Results 11 to 20 of about 5,756 (231)

Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background After a loading dose of ticagrelor, the rate of high on‐treatment platelet reactivity remains elevated, which increases periprocedural myocardial infarction and injury.
Moazez J. Marian, Hussein Abu Daya, Arka Chatterjee, Firas Al Solaiman, Mark F. Sasse, William S. Fonbah, Raymond W. Workman, Brittany E. Johnson, Sarah E. Carlson, Brigitta C. Brott, Sumanth D. Prabhu, Massoud A. Leesar   +11 more
doaj   +2 more sources

A rare case of eptifibatide-induced thrombocytopenia [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2021
Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar, Kira MacDougall, Mira Alsheikh, Sara Parylo, Yevgeniy Skaradinskiy   +4 more
doaj   +3 more sources

Eptifibatide-induced acute profound thrombocytopenia in a patient with left main artery plaque rupture complicated by cardiogenic shock and gastrointestinal bleeding

Journal of Clinical and Preventive Cardiology, 2021
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal, William Van Gaal, Francis A Ponnuthurai   +2 more
doaj   +2 more sources

Stabilization of eptifibatide by cosolvents [PDF]

International Journal of Pharmaceutics, 2001
Eptifibatide is a potent and highly specific inhibitor of platelet receptor glycoprotein IIb/IIIa and is indicated in the treatment of acute coronary syndrome. The commercial product Integrilin(R) (eptifibatide) Injection requires a cold/refrigerator storage condition.
Luwei Zhao, Samuel H. Yalkowsky
openalex   +4 more sources

Intracoronary Versus Intravenous Administration of Eptifibatide During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

Acta Medica Iranica, 2020
Introduction: Platelets activation and aggregation play a major role in thrombosis formation of coronary arteries in patients with Acute Coronary Syndrome (ACS)   and is responsible for most ischemic complications during PCI.
tooran makhdoumi
doaj   +2 more sources

Clinical and economic studies of eptifibatide in coronary stenting

Therapeutics and Clinical Risk Management, 2014
Tilak Pasala, Prasongchai Sattayaprasert, Pradeep K Bhat, Ganesh Athappan, Sanjay Gandhi The Heart and Vascular Center, Case Western Reserve University/MetroHealth, Cleveland, OH, USA Abstract: Platelet adhesion and aggregation at the site of coronary ...
Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S   +4 more
doaj   +5 more sources

Addition of eptifibatide and manual thrombus aspiration to ticagrelor does not improve long-term survival after STEMI treated with primary PCI [PDF]

Frontiers in Pharmacology
Background: Current guidelines recommend that glycoprotein IIb/IIIa inhibitor (GPI) and manual aspiration thrombectomy should not be routinely used in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous ...
Paul-Adrian Călburean, Paul-Adrian Călburean, Paul Grebenișan, Ioana-Andreea Nistor, Krisztina Pal, Krisztina Pal, Victor Vacariu, Reka-Katalin Drincal, Alissa Anamaria Ion, István Adorján, Tiberiu Oltean, László Hadadi   +11 more
doaj   +2 more sources

Comparison of eptifibatide and abciximab with decision analysis [PDF]

American Journal of Health-System Pharmacy, 2001
Dorothy H. Wong
openalex   +4 more sources

Systematic adjudication of myocardial infarction end-points in an international clinical trial [PDF]

Current Controlled Trials in Cardiovascular Medicine, 2001
Background Clinical events committees (CEC) are used routinely to adjudicate suspected end-points in cardiovascular trials, but little information has been published about the various processes used.
Lee Kerry L, Corbalon Ramón, Widimsky Petr, Bhapkar Manju, DeJong Ingrid, Granger Christopher B, Tardiff Barbara E, Crenshaw Brian S, Berdan Lisa G, Kleiman Neal S, Akkerhuis Martijn, Harrington Robert A, Mahaffey Kenneth W, Deckers Jaap W, Simoons Maarten L, Topol Eric J, Califf Robert M   +16 more
doaj   +6 more sources

In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors. [PDF]

HIV Med
Abstract Introduction People with HIV currently face a tenfold higher risk of developing cardiovascular disease (CVD) than those without HIV. Studies have shown various off‐target effects of antiretroviral treatment (ART) on the cardiovascular system, but little is known about the effects of currently used integrase strand transfer inhibitors (INSTIs ...
Keniyopoullos R, Khawaja AA, Boffito M, Emerson M.   +3 more
europepmc   +2 more sources